

Complete Airway Repositioning and/or Expansion (CARE): A Novel Oral Appliance Therapy for Headaches Administered by Dentists



Seth Heckman MD^{*}, Dean Raio DDS *University of Alberta Department of Family Medicine

INTRODUCTION

- Temporomandibular Joint Dysfunction (TMD) is a common problem that exacerbates headaches and significantly decreases quality of life
- CARE (Vivos Therapeutics; Denver CO) is a series of oral appliances that stimulate palatal expansion via applying gentle pressure at the dento-palatal junction
- Via palatal expansion mandibular adjustment and repositioning as well as muscle relaxation decreased tension at the temporo-mandibular joint is possible
- Dentists proficient in the use of CARE deploying it to patients for headache relief have reported significant anecdotal improvements in their patients

Table 1. Demographics

<u>Age- median years (Interquartile Range)</u>	44 (33-54)
<u>Gender #(%)</u>	
Male	43 (35.5)
Female	76 (62.8)
Missing	2 (1.7)
Ethnicity #(%)	
Caucasian	105 (95.5)
Other	5 (4.5)
Pre-Treatment Headache Impact #(%)	
Little or No Impact (<50)	33 (27.3)
Some Impact (50-55)	26 (21.5)
Substantial Impact (56-59)	11 (9.1)
Severe Impact (>59)	48 (39.7)

• Investigators sought to evaluate claims of headache improvement with CARE use via a database review



Figure 1. The Daytime-Nighttime Appliance- A CARE system with Class 1 FDA registration for jaw expansion and tooth alignment

METHODS & MATERIALS

RESULTS

- 121 patients were included for review from 4 dental practices across the United States and Canadademographics in Table 1
- Median treatment duration was 357 days (Interquartile Range 192-722)
- Compliance was high- median 75% compliance with hours worn/night and median 100% compliance with nights/week worn
- Median HIT6 Scores decreased from 56 to 40 for a decrease of 16 or 28.6%, P<.05
- 60.7% of patients decreased their headache impact severity category
- 63.5% of patients who started treatment with at least some headache impact demonstrated clinical cure (final score little to no impact)
- IRB exemption determination made by WCG IRB (Protocol ID 20222934)
- Investigators conducted a retrospective review of the Vivos Airway Intelligence Service database- a prospectively collected, real-world database of patients who underwent CARE treatment
- Included patients 18 years of age and older undergoing treatment for headaches with available pre-treatment HIT-6 scores as well as interval or post treatment HIT-6 scores after completing at least 6 months of therapy
- Demographics, treatment information, and HIT-6 scores were reviewed
- Descriptive statistics were generated and statistical significance was assessed via related-samples Wilcoxon Signed rank test



Figure 2. The Headache Impact Test (HIT-6) is a brief tool validated to assess the impact of headaches in clinical research and practice





Figure 3. Patients in each HIT-6 impact category pre and post treatment

CONCLUSION

• CARE treatment significantly decreases headache impacts

- Study is limited by sample size, selection bias, lack of medical histories especially including prior and adjunctive treatment, and limited courses of therapy
- Larger cohorts and clinical trials are warranted to determine the role CARE might play and how to optimize patient candidacy
- Enhanced medical-dental collaboration is required to optimize this potential opportunity in headache treatment

Presented at the 98th Annual Session of the Greater New York Dental Meeting in 2022